中際旭創(300308.SZ):原減持計劃期滿 特定股東擬繼續減持不超0.8%的股份
格隆匯3月17日丨中際旭創(300308.SZ)公佈,2020年3月17日,公司收到特定股東凱風進取、凱風萬盛出具的《關於股份減持計劃期滿暨擬繼續減持的告知函》。
截至公告日,特定股東凱風進取、凱風萬盛在減持計劃實施期間,通過集中競價及大宗交易方式累計減持公司股份1835.0778萬股,佔公司總股本的2.5731%,此次減持計劃期限已屆滿。
另外,凱風進取計劃未來六個月內以大宗交易或集中競價方式減持公司股份不超過378.7648萬股,佔公司總股本的0.53%;凱風萬盛計劃未來六個月內以大宗交易或集中競價方式減持公司股份不超過189.8477萬股,佔公司總股本的0.27%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.